U.S. Markets closed
  • S&P Futures

    4,068.75
    -13.00 (-0.32%)
     
  • Dow Futures

    34,340.00
    -89.00 (-0.26%)
     
  • Nasdaq Futures

    12,011.50
    -51.25 (-0.42%)
     
  • Russell 2000 Futures

    1,877.30
    -6.40 (-0.34%)
     
  • Crude Oil

    81.16
    -0.06 (-0.07%)
     
  • Gold

    1,814.10
    -1.10 (-0.06%)
     
  • Silver

    22.88
    +0.03 (+0.15%)
     
  • EUR/USD

    1.0516
    -0.0012 (-0.1157%)
     
  • 10-Yr Bond

    3.5290
    -0.1740 (-4.70%)
     
  • Vix

    19.84
    -0.74 (-3.60%)
     
  • GBP/USD

    1.2239
    -0.0017 (-0.1395%)
     
  • USD/JPY

    135.3970
    +0.0910 (+0.0673%)
     
  • BTC-USD

    17,018.46
    -137.12 (-0.80%)
     
  • CMC Crypto 200

    403.74
    -2.41 (-0.59%)
     
  • FTSE 100

    7,558.49
    -14.56 (-0.19%)
     
  • Nikkei 225

    27,816.32
    -409.76 (-1.45%)
     

Is AbbVie a Buy?

Is AbbVie a Buy?

Drugmaker AbbVie (NYSE: ABBV) is one of the largest healthcare stocks in the world, with a market cap of over $250 billion. AbbVie last reported its earnings in July. Humira remains key to AbbVie's business for now, generating $5.4 billion this past quarter, nearly three times the $1.8 billion Skyrizi and Rinvoq generated.